We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
16.38 USD -0.06 ( 0.36%)
Last update at 2026-11-12T15:46:00Z
VOLUME
194529
Market Cap
3170.40M
P/E
58.95

Momentum Score

…

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
16.25
Low
16.46
High
52 Week Price Range
10.71
Low
19.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Sotera Health provides sterilization and laboratory testing services for medical device, pharmaceutical and healthcare customers through businesses such as Sterigenics and Nelson Labs. Long-term growth may be supported by rising global demand for medical products, continued outsourcing of complex sterilization and testing, and regulatory focus on product safety, which could support recurring revenue and utilization trends.
Key investment risks include regulatory and environmental scrutiny of ethylene oxide operations, potential plant shutdowns or remediation costs, operational concentration in sterilization technologies and related execution risk.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
16.44
Dividend Yield
-
Revenue TTM
1076.87M
Revenue Per Share
3.83
Gross Profit TTM
557.00M
Debt / Equity
5.24
ROE
13.88%
Net Debt
2025.40M
ROCE
8.56%
Diluted EPS TTM
0.19

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -243.11M 175.72M -38.86M -0.92M 24.22M
Minority interest 0.00M -0.24M 15.90M 15.07M 14.76M
Net income -233.57M 116.88M -37.49M -20.43M -5.87M
Selling general administrative 245.71M 198.16M 178.53M 147.48M 133.36M
Gross profit 557.00M 518.67M 443.57M 395.43M 357.25M
Reconciled depreciation 145.55M 63.78M 143.56M 146.72M 146.82M
Ebit 248.35M 256.73M 206.02M 183.60M 169.78M
Ebitda 317.73M 335.71M 274.46M 343.35M 316.60M
Depreciation and amortization 69.38M 78.98M 68.44M 159.76M 146.82M
Non operating income net other - -6.83M - - -
Operating income 248.35M 256.73M 206.02M 183.60M 80.85M
Other operating expenses 755.34M 674.75M 612.14M 588.94M 580.24M
Interest expense 80.14M 74.19M 215.26M 157.73M 143.33M
Tax provision -9.54M 58.59M -1.37M 19.51M 30.10M
Net interest income -80.14M -74.19M -215.26M -157.73M -143.33M
Income tax expense -9.54M 58.59M -1.37M 19.51M 30.10M
Total revenue 1003.69M 931.48M 818.16M 778.33M 746.15M
Total operating expenses 308.65M 261.94M 237.55M 206.04M 191.34M
Cost of revenue 446.68M 412.81M 374.59M 382.90M 388.90M
Total other income expense net -491.46M -81.02M -244.88M -184.51M 1.63M
Net income from continuing ops -233.57M 117.12M -37.49M -20.43M -5.88M
Net income applicable to common shares -233.57M 116.88M -38.62M -20.85M -5.87M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 3130.42M 3117.70M 2789.50M 2761.28M 2580.67M
Intangible assets 416.32M 491.26M 598.84M 643.37M 696.01M
Other current assets 28.09M 93.09M 76.57M 86.73M 10.44M
Total liab 2686.69M 2767.47M 2203.41M 2306.70M 3221.81M
Total stockholder equity 443.73M 350.24M 586.10M 454.57M -642.57M
Deferred long term liab - - 134.50M - -
Other current liab 126.62M 498.89M 69.17M 71.59M 60.74M
Common stock 2.86M 2.86M 2.86M 2.86M 2.32M
Capital stock 2.86M 2.86M 2.86M 2.86M 2.32M
Retained earnings -654.44M -705.82M -472.25M -589.13M -550.51M
Other liab - 150.25M 298.71M 253.81M 253.44M
Good will 1111.19M 1101.77M 1120.32M 1115.94M 1035.87M
Other assets - 82.91M 33.63M 77.15M 18.81M
Cash 301.65M 396.29M 106.92M 102.45M 62.86M
Total current liabilities 230.65M 791.57M 161.16M 140.60M 123.99M
Current deferred revenue 13.49M 12.14M 8.67M 6.06M 3.63M
Net debt 2025.40M 1557.22M 1636.61M 1722.34M 2785.51M
Short term debt 19.50M 206.40M 10.45M 10.56M 17.62M
Short long term debt 4.80M 197.12M - - 16.33M
Short long term debt total 2327.06M 1953.51M 1743.53M 1824.79M 2848.38M
Other stockholder equity 1188.00M 1159.85M 1139.05M 1134.68M -0.39M
Property plant equipment - 796.75M 690.74M 651.86M 577.64M
Total current assets 557.24M 645.01M 345.96M 315.01M 252.35M
Long term investments - 0.00M 9.40M 13.46M -
Net tangible assets - -1242.80M -1133.07M -1307.00M -2374.45M
Short term investments 0.71M - - 13.46M -
Net receivables 175.52M 118.48M 108.18M 91.73M 111.58M
Long term debt 2223.67M 1747.12M 1743.53M 1824.79M 2800.87M
Inventory 51.98M 37.15M 54.29M 34.09M 37.40M
Accounts payable 71.04M 74.14M 72.87M 52.40M 42.00M
Accumulated other comprehensive income -92.68M -106.65M -83.57M -93.84M -94.39M
Common stock total equity - - 2.86M 2.86M 2.32M
Retained earnings total equity - - -472.25M - -
Treasury stock - - -33.55M - -
Non currrent assets other 59.47M 74.55M 18.34M 9.30M 12.24M
Non current assets total 2573.18M 2472.70M 2443.54M 2446.26M 2328.32M
Capital lease obligations 98.58M 87.81M 84.34M 84.44M 31.17M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -181.90M -159.83M -158.69M -57.26M 96.64M
Change to liabilities 1.11M 31.09M -6.02M -8.97M 15.12M
Total cashflows from investing activities -181.90M -159.83M -158.69M -57.26M 96.64M
Net borrowings 200.00M -100.00M -1027.33M 583.52M -14.63M
Total cash from financing activities 197.76M -117.29M 73.43M -126.03M -191.86M
Change to operating activities 418.57M -12.59M -3.36M -3.09M -5.87M
Net income -233.57M 117.12M -37.49M -20.43M -5.88M
Change in cash 289.37M 4.47M 39.43M -33.76M 20.67M
Begin period cash flow 106.92M 102.45M 63.02M 96.79M 76.12M
End period cash flow 396.29M 106.92M 102.45M 63.02M 96.79M
Total cash from operating activities 277.96M 281.55M 120.58M 149.04M 119.56M
Issuance of capital stock 0.00M 0.00M 1155.96M - -
Depreciation 145.55M 150.90M 143.56M 146.72M 146.82M
Other cashflows from investing activities 0.03M -0.70M -0.70M -0.70M 6.43M
Dividends paid - 0.00M -150.00M -691.17M 175.84M
Change to inventory 14.44M -20.25M 3.78M -0.28M -7.04M
Change to account receivables -12.55M -15.51M 1.94M 11.76M -2.91M
Sale purchase of stock -0.39M -1.43M -34.00M - -
Other cashflows from financing activities 198.19M -15.85M 278.80M 3126.22M -1.38M
Change to netincome -51.13M 177.01M 13.81M 21.18M -34.02M
Capital expenditures 182.38M 102.16M 53.51M 57.26M 72.61M
Change receivables - -15.51M - - -
Cash flows other operating - -7.93M - - -
Cash and cash equivalents changes - 4.43M - - -
Change in working capital 409.23M -12.59M -11.79M -8.35M 4.04M
Stock based compensation 21.21M 13.87M 10.99M 6.88M 6.94M
Other non cash items 9.49M 15.96M 38.68M 43.21M 12.96M
Free cash flow 95.58M 179.38M 67.08M 91.78M 46.95M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SHC
Sotera Health Co
-0.06
0.36%
16.38 58.95 15.67 3.04 7.20 4.98 12.85
TMO
Thermo Fisher Scientific Inc
-15.12
2.11%
702.59 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation
-1.34
0.57%
233.97 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd
-
-%
24.91 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd
-0.17
0.68%
24.93 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Sotera Health Co

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

9100 South Hills Boulevard, Broadview Heights, OH, United States, 44147

440 262 1410

3000

Name Title Year Born
Mr. Michael B. Petras Jr. Chairman & CEO 1969
Mr. Michael P. Rutz Pres of Sterigenics 1971
Mr. Michael F. Biehl Interim Chief Financial Officer 1956
Mr. Kevin Theriault Sr. VP of Operations NA
Mr. Robert G. Hauzie Chief Information Officer NA
Joseph Vitale VP of Investor Relations NA
Mr. Alexander Dimitrief Sr. VP & Gen. Counsel 1959
Ms. Kristin A. Gibbs Chief Marketing Officer NA
Mr. William Lehmann Jr., J.D., M.B.A., MBA Sr. VP of Strategy & Corp. Devel. 1966
Ms. Sally R. Turner Chief HR Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…